No worries.The announcement last Monday was the FDA giving BIT...

No worries.
The announcement last Monday was the FDA giving BIT 225 the green light to be investigated further.

The extract below is from Biotron's announcement on May 2nd which echoed the March announcement.

"In March 2022 the Company submitted a proposal to the USA Food and Drug Administration (FDA) to conduct a human clinical trial to assess the efficacy of BIT225 for the treatment of COVID-19 under the Coronavirus Treatment Acceleration Program, a special emergency program for potential coronavirus therapies. A response is expected shortly and, once received, the Company will be in a position to determine its capital requirements for the human clinical program funding which will be sought from potential partners and non-equity funding sources.

In terms of funding the C19 phase 2 trial, Biotron will have been in discussions with potential partners/big pharma since the announcement back in November.
Since the May 2nd announcement, they have had 3 extremely positive trial results to present to potential partners for funding which if successful, would be presented to the FDA to continue through the CTAP process.